Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 29,526 shares of the biopharmaceutical company’s stock after buying an additional 236 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 1.7% of Washington Trust Advisors Inc.’s portfolio, making the stock its 20th largest holding. Washington Trust Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $18,726,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital International Investors boosted its stake in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares during the period. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after buying an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the period. Finally, Franklin Resources Inc. increased its position in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after acquiring an additional 149,124 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $521.00 on Monday. The stock has a market cap of $56.25 billion, a P/E ratio of 13.26, a P/E/G ratio of 1.91 and a beta of 0.31. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The business has a fifty day simple moving average of $554.18 and a 200-day simple moving average of $631.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $9.55 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, June 2nd. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price objective on the stock. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, June 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group dropped their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $822.58.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.